Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer
Status PubMed-not-MEDLINE Jazyk angličtina Země Švýcarsko Médium electronic-ecollection
Typ dokumentu časopisecké články, přehledy
PubMed
26300886
PubMed Central
PMC4528281
DOI
10.3389/fimmu.2015.00402
Knihovny.cz E-zdroje
- Klíčová slova
- ATP, ER stress response, HSPs, autophagy, calreticulin, type I interferon,
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
It is now clear that human neoplasms form, progress, and respond to therapy in the context of an intimate crosstalk with the host immune system. In particular, accumulating evidence demonstrates that the efficacy of most, if not all, chemo- and radiotherapeutic agents commonly employed in the clinic critically depends on the (re)activation of tumor-targeting immune responses. One of the mechanisms whereby conventional chemotherapeutics, targeted anticancer agents, and radiotherapy can provoke a therapeutically relevant, adaptive immune response against malignant cells is commonly known as "immunogenic cell death." Importantly, dying cancer cells are perceived as immunogenic only when they emit a set of immunostimulatory signals upon the activation of intracellular stress response pathways. The emission of these signals, which are generally referred to as "damage-associated molecular patterns" (DAMPs), may therefore predict whether patients will respond to chemotherapy or not, at least in some settings. Here, we review clinical data indicating that DAMPs and DAMP-associated stress responses might have prognostic or predictive value for cancer patients.
Zobrazit více v PubMed
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57–70.10.1016/S0092-8674(00)81683-9 PubMed DOI
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 27:5904–12.10.1038/onc.2008.271 PubMed DOI PMC
Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature (2013) 501:328–37.10.1038/nature12624 PubMed DOI PMC
Sautes-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev (2011) 30:13–25.10.1007/s10555-011-9279-y PubMed DOI
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (2011) 331:1565–70.10.1126/science.1203486 PubMed DOI
Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol (2014) 27:16–25.10.1016/j.coi.2014.01.004 PubMed DOI PMC
Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6:715–27.10.1038/nri1936 PubMed DOI
Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol (2013) 34:471–81.10.1016/j.it.2013.06.005 PubMed DOI
Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautes-Fridman C, et al. Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother (2014) 63:991–7.10.1007/s00262-014-1590-3 PubMed DOI PMC
Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12:298–306.10.1038/nrc3245 PubMed DOI
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1:1323–43.10.4161/onci.22009 PubMed DOI PMC
Senovilla L, Aranda F, Galluzzi L, Kroemer G. Impact of myeloid cells on the efficacy of anticancer chemotherapy. Curr Opin Immunol (2014) 30:24–31.10.1016/j.coi.2014.05.009 PubMed DOI
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 11:215–33.10.1038/nrd3626 PubMed DOI
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 39:74–88.10.1016/j.immuni.2013.06.014 PubMed DOI
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buque A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget (2014) 5:12472–508. PubMed PMC
Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology (2013) 2:e25396.10.4161/onci.25396 PubMed DOI PMC
Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res (2011) 71:4821–33.10.1158/0008-5472.CAN-11-0950 PubMed DOI
Dudek AM, Garg AD, Krysko DV, De Ruysscher D, Agostinis P. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev (2013) 24:319–33.10.1016/j.cytogfr.2013.01.005 PubMed DOI
Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 2:e23510.10.4161/onci.23510 PubMed DOI PMC
Fucikova J, Moserova I, Truxova I, Hermanova I, Vancurova I, Partlova S, et al. High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer (2014) 135:1165–77.10.1002/ijc.28766 PubMed DOI
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 3:e27878.10.4161/onci.27878 PubMed DOI PMC
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol (2013) 31:51–72.10.1146/annurev-immunol-032712-100008 PubMed DOI
Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 3:e955691.10.4161/21624011.2014.955691 PubMed DOI PMC
Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991–1045.10.1146/annurev.iy.12.040194.005015 PubMed DOI
Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 30:61–9.10.1007/s10555-011-9273-4 PubMed DOI
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 12:860–75.10.1038/nrc3380 PubMed DOI
Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors (2013) 39:355–67.10.1002/biof.1125 PubMed DOI
Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2014) 21:26–38.10.1038/cdd.2013.48 PubMed DOI PMC
Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature (2010) 464:104–7.10.1038/nature08780 PubMed DOI PMC
Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol (2012) 13:780–8.10.1038/nrm3479 PubMed DOI
Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res (2005) 65:1018–26. PubMed
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2007) 13:54–61.10.1038/nm1523 PubMed DOI
Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood (2007) 109:4839–45.10.1182/blood-2006-10-054221 PubMed DOI PMC
Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 28:578–90.10.1038/emboj.2009.1 PubMed DOI PMC
Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol (2011) 32:157–64.10.1016/j.it.2011.01.005 PubMed DOI
Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 31:1062–79.10.1038/emboj.2011.497 PubMed DOI PMC
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1:699–716.10.4161/onci.20696 PubMed DOI PMC
Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, et al. Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 3:e29179.10.4161/onci.29179 PubMed DOI PMC
Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med (2014) 20:1301–9.10.1038/nm.3708 PubMed DOI
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 15(7):405–14.10.1038/nri3845 PubMed DOI
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 15:1170–8.10.1038/nm.2028 PubMed DOI
Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 334:1573–7.10.1126/science.1208347 PubMed DOI
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13:1050–9.10.1038/nm1622 PubMed DOI
Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol (2013) 59:583–94.10.1016/j.jhep.2013.03.033 PubMed DOI
Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity (2012) 36:635–45.10.1016/j.immuni.2012.03.008 PubMed DOI
Tufi R, Panaretakis T, Bianchi K, Criollo A, Fazi B, Di Sano F, et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ (2008) 15:274–82.10.1038/sj.cdd.4402275 PubMed DOI
Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol (2012) 13:89–102.10.1038/nrm3270 PubMed DOI
Kepp O, Semeraro M, Bravo-San Pedro JM, Bloy N, Buque A, Huang X, et al. eIF2alpha phosphorylation as a biomarker of immunogenic cell death. Semin Cancer Biol (2015).10.1016/j.semcancer.2015.02.004 PubMed DOI
Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem (2001) 276:17163–71.10.1074/jbc.M011547200 PubMed DOI
Doody AD, Kovalchin JT, Mihalyo MA, Hagymasi AT, Drake CG, Adler AJ. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol (2004) 172:6087–92.10.4049/jimmunol.172.10.6087 PubMed DOI PMC
Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle (2007) 6:1962–5.10.4161/cc.6.16.4601 PubMed DOI
Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol (2000) 12:1539–46.10.1093/intimm/12.11.1539 PubMed DOI
Duo CC, Gong FY, He XY, Li YM, Wang J, Zhang JP, et al. Soluble calreticulin induces tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFkappaB signaling pathways. Int J Mol Sci (2014) 15:2916–28.10.3390/ijms15022916 PubMed DOI PMC
Multhoff G, Botzler C, Wiesnet M, Eissner G, Issels R. CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood (1995) 86:1374–82. PubMed
Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J, Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 158:4341–50. PubMed
Segawa K, Kurata S, Yanagihashi Y, Brummelkamp TR, Matsuda F, Nagata S. Caspase-mediated cleavage of phospholipid flippase for apoptotic phosphatidylserine exposure. Science (2014) 344:1164–8.10.1126/science.1252809 PubMed DOI
Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J (2010) 24:665–83.10.1096/fj.09-145482 PubMed DOI PMC
Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol (2006) 177:3582–9.10.4049/jimmunol.177.6.3582 PubMed DOI
Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM, et al. Calreticulin expression in neuroblastoma – a novel independent prognostic factor. Ann Oncol (2005) 16:314–21.10.1093/annonc/mdi062 PubMed DOI
Garg AD, Elsen S, Krysko DV, Vandenabeele P, De Witte P, Agostinis P. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget (2015). PubMed PMC
Peng RQ, Chen YB, Ding Y, Zhang R, Zhang X, Yu XJ, et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol (2010) 16:2428–34.10.3748/wjg.v16.i19.2428 PubMed DOI PMC
Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res (2010) 70:9062–72.10.1158/0008-5472.CAN-10-1825 PubMed DOI
Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis (2010) 1:e104.10.1038/cddis.2010.82 PubMed DOI PMC
Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother (2012) 61:855–64.10.1007/s00262-011-1146-8 PubMed DOI PMC
Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression. J Biol Chem (2010) 285:25458–66.10.1074/jbc.M110.139345 PubMed DOI PMC
Chen WS, Chen CC, Chen LL, Lee CC, Huang TS. Secreted heat shock protein 90alpha (HSP90alpha) induces nuclear factor-kappaB-mediated TCF12 protein expression to down-regulate E-cadherin and to enhance colorectal cancer cell migration and invasion. J Biol Chem (2013) 288:9001–10.10.1074/jbc.M112.437897 PubMed DOI PMC
Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2:63ra94.10.1126/scitranslmed.3001375 PubMed DOI PMC
Eric A, Juranic Z, Milovanovic Z, Markovic I, Inic M, Stanojevic-Bakic N, et al. Effects of humoral immunity and calreticulin overexpression on postoperative course in breast cancer. Pathol Oncol Res (2009) 15:89–90.10.1007/s12253-008-9112-2 PubMed DOI
Chen CN, Chang CC, Su TE, Hsu WM, Jeng YM, Ho MC, et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol (2009) 16:524–33.10.1245/s10434-008-0243-1 PubMed DOI
Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell (2009) 138:286–99.10.1016/j.cell.2009.05.045 PubMed DOI PMC
Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, et al. CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep (2012) 28:465–72.10.3892/or.2012.1831 PubMed DOI
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang D, et al. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol Sci (2015) 16:3391–404.10.3390/ijms16023391 PubMed DOI PMC
Stebbing J, Bower M, Gazzard B, Wildfire A, Pandha H, Dalgleish A, et al. The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors. Clin Exp Immunol (2004) 138:312–6.10.1111/j.1365-2249.2004.02619.x PubMed DOI PMC
Schardt JA, Weber D, Eyholzer M, Mueller BU, Pabst T. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res (2009) 15:3834–41.10.1158/1078-0432.CCR-08-2870 PubMed DOI
Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 337:1678–84.10.1126/science.1224922 PubMed DOI
Davies MP, Barraclough DL, Stewart C, Joyce KA, Eccles RM, Barraclough R, et al. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer (2008) 123:85–8.10.1002/ijc.23479 PubMed DOI
Mozos A, Roue G, Lopez-Guillermo A, Jares P, Campo E, Colomer D, et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma. Am J Pathol (2011) 179:2601–10.10.1016/j.ajpath.2011.07.031 PubMed DOI PMC
Jiang L, Huang S, Li W, Zhang D, Zhang S, Zhang W, et al. Expression of autophagy and ER stress-related proteins in primary salivary adenoid cystic carcinoma. Pathol Res Pract (2012) 208:635–41.10.1016/j.prp.2012.07.008 PubMed DOI
Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Yoshimastu T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer (2005) 49:55–62.10.1016/j.lungcan.2004.12.011 PubMed DOI
He Y, Correa AM, Raso MG, Hofstetter WL, Fang B, Behrens C, et al. The role of PKR/eIF2alpha signaling pathway in prognosis of non-small cell lung cancer. PLoS One (2011) 6:e24855.10.1371/journal.pone.0024855 PubMed DOI PMC
Ferrer-Ferrer M, Malespin-Bendana W, Ramirez V, Gonzalez MI, Carvajal A, Une C. Polymorphisms in genes coding for HSP-70 are associated with gastric cancer and duodenal ulcer in a population at high risk of gastric cancer in Costa Rica. Arch Med Res (2013) 44:467–74.10.1016/j.arcmed.2013.08.008 PubMed DOI
Nevadunsky NS, Korneeva I, Caputo T, Witkin SS. Mannose-binding lectin codon 54 genetic polymorphism and vaginal protein levels in women with gynecologic malignancies. Eur J Obstet Gynecol Reprod Biol (2012) 163:216–8.10.1016/j.ejogrb.2012.04.020 PubMed DOI PMC
Hong B, Chen S, Qi Y, Zhu J, Lin J. Association of THBS1 rs1478605 T>C in 5’-untranslated regions with the development and progression of gastric cancer. Biomed Rep (2015) 3:207–14.10.3892/br.2015.414 PubMed DOI PMC
Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res (2012) 72:3967–76.10.1158/0008-5472.CAN-12-0851 PubMed DOI
Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 12:829–46.10.1038/nrd4145 PubMed DOI
Schardt JA, Mueller BU, Pabst T. Activation of the unfolded protein response in human acute myeloid leukemia. Methods Enzymol (2011) 489:227–43.10.1016/B978-0-12-385116-1.00013-3 PubMed DOI
Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature (2014) 508:103–7.10.1038/nature13119 PubMed DOI PMC
Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology (2012) 1:1557–76.10.4161/onci.22428 PubMed DOI PMC
Aranda F, Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Tartour E, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology (2013) 2:e26621.10.4161/onci.26621 PubMed DOI PMC
Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol (2009) 5:763–74.10.2217/fon.09.46 PubMed DOI
Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 20:4169–80.10.1200/JCO.2002.09.134 PubMed DOI
Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother (2006) 55:958–68.10.1007/s00262-005-0084-8 PubMed DOI PMC
Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 study group. J Clin Oncol (2008) 26:955–62.10.1200/JCO.2007.11.9941 PubMed DOI
Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, et al. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. J Transl Med (2010) 8:9.10.1186/1479-5876-8-9 PubMed DOI PMC
Mazzaferro V, Coppa J, Carrabba MG, Rivoltini L, Schiavo M, Regalia E, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res (2003) 9:3235–45. PubMed
Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer (2007) 109:77–83.10.1002/cncr.22389 PubMed DOI
Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci (2007) 52:1964–72.10.1007/s10620-006-9205-2 PubMed DOI
Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, et al. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer (2008) 98:1336–41.10.1038/sj.bjc.6604266 PubMed DOI PMC
Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet (2008) 372:145–54.10.1016/S0140-6736(08)60697-2 PubMed DOI
Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2013) 19:205–14.10.1158/1078-0432.CCR-11-3358 PubMed DOI
Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2014) 16:274–9.10.1093/neuonc/not203 PubMed DOI PMC
Janetzki S, Palla D, Rosenhauer V, Lochs H, Lewis JJ, Srivastava PK. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 88:232–8.10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8 PubMed DOI
Papewalis C, Jacobs B, Wuttke M, Ullrich E, Baehring T, Fenk R, et al. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo. J Immunol (2008) 180:1462–70.10.4049/jimmunol.180.3.1462 PubMed DOI
Guillot B, Portales P, Thanh AD, Merlet S, Dereure O, Clot J, et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol (2005) 152:690–6.10.1111/j.1365-2133.2005.06512.x PubMed DOI
Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS One (2014) 9:e87794.10.1371/journal.pone.0087794 PubMed DOI PMC
Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, et al. Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1. Immunity (2014) 40:961–73.10.1016/j.immuni.2014.05.003 PubMed DOI
Xu HC, Grusdat M, Pandyra AA, Polz R, Huang J, Sharma P, et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity. Immunity (2014) 40:949–60.10.1016/j.immuni.2014.05.004 PubMed DOI
Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J Immunol (2011) 187:2540–7.10.4049/jimmunol.1100926 PubMed DOI PMC
Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, et al. Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res (2013) 73:5647–56.10.1158/0008-5472.CAN-12-3788 PubMed DOI
Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 122:575–85.10.1172/JCI61034 PubMed DOI PMC
Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst (2012) 104:1796–807.10.1093/jnci/djs436 PubMed DOI PMC
Yuan MM, Xu YY, Chen L, Li XY, Qin J, Shen Y. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis. BMC Cancer (2015) 15:245.10.1186/s12885-015-1262-5 PubMed DOI PMC
Hsu WM, Huang CC, Wu PY, Lee H, Huang MC, Tai MH, et al. Toll-like receptor 3 expression inhibits cell invasion and migration and predicts a favorable prognosis in neuroblastoma. Cancer Lett (2013) 336:338–46.10.1016/j.canlet.2013.03.024 PubMed DOI
Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 71:1607–14.10.1158/0008-5472.CAN-10-3490 PubMed DOI
Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer (2011) 47:1203–10.10.1016/j.ejca.2010.12.011 PubMed DOI
Dai J, Hu Z, Dong J, Xu L, Pan S, Jiang Y, et al. Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese. Int J Cancer (2012) 130:671–6.10.1002/ijc.26067 PubMed DOI
Zidi S, Verdi H, Yilmaz-Yalcin Y, Yazici AC, Gazouani E, Mezlini A, et al. Impact of toll-like receptors 2/3/4/9, IL-1-alpha/beta and TNF-alpha polymorphisms in cervical cancer susceptibility in Tunisia : genetic polymorphisms implicated in the occurence of cervical cancer. Pathol Oncol Res (2014).10.1007/s12253-014-9793-7 PubMed DOI
Yeyeodu ST, Kidd LR, Oprea-Ilies GM, Burns BG, Vancleave TT, Shim JY, et al. IRAK4 and TLR3 sequence variants may alter breast cancer risk among African-American women. Front Immunol (2013) 4:338.10.3389/fimmu.2013.00338 PubMed DOI PMC
Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, Obrenovic M, et al. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis (2014) 20:416–24.10.1111/odi.12144 PubMed DOI
Li G, Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumour Biol (2013) 34:1589–94.10.1007/s13277-013-0689-z PubMed DOI
Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer (2012) 130:2974–80.10.1002/ijc.26314 PubMed DOI PMC
Lu S, Pardini B, Cheng B, Naccarati A, Huhn S, Vymetalkova V, et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLoS One (2014) 9:e111061.10.1371/journal.pone.0111061 PubMed DOI PMC
Fujita M, Scheurer ME, Decker SA, McDonald HA, Kohanbash G, Kastenhuber ER, et al. Role of type 1 IFNs in antiglioma immunosurveillance – using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res (2010) 16:3409–19.10.1158/1078-0432.CCR-10-0644 PubMed DOI PMC
Kim HJ, Bae JS, Chang IH, Kim KD, Lee J, Shin HD, et al. Sequence variants of toll-like receptor 4 (TLR4) and the risk of prostate cancer in Korean men. World J Urol (2012) 30:225–32.10.1007/s00345-011-0690-3 PubMed DOI
Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, et al. Trial watch: immunostimulatory cytokines. Oncoimmunology (2013) 2:e24850.10.4161/onci.24850 PubMed DOI PMC
Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, et al. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 3:e29030.10.4161/onci.29030 PubMed DOI PMC
Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 8:3723–8.10.4161/cc.8.22.10026 PubMed DOI
Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ (2014) 21:79–91.10.1038/cdd.2013.75 PubMed DOI PMC
Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology (2012) 1:393–5.10.4161/onci.19070 PubMed DOI PMC
Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. EMBO J (2015) 34:856–80.10.15252/embj.201490784 PubMed DOI PMC
Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res (2015) 3:254–65.10.1158/2326-6066.CIR-14-0018 PubMed DOI
Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 461:282–6.10.1038/nature08296 PubMed DOI PMC
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 38:729–41.10.1016/j.immuni.2013.03.003 PubMed DOI
Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. Oncoimmunology (2013) 2:e24568.10.4161/onci.24568 PubMed DOI PMC
Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 70:855–8.10.1158/0008-5472.CAN-09-3566 PubMed DOI
Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 13:343–51.10.1038/ni.2224 PubMed DOI
Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends Immunol (2012) 33:231–7.10.1016/j.it.2012.02.009 PubMed DOI
Dardano A, Falzoni S, Caraccio N, Polini A, Tognini S, Solini A, et al. 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J Clin Endocrinol Metab (2009) 94:695–8.10.1210/jc.2008-1322 PubMed DOI
Wiley JS, Dao-Ung LP, Gu BJ, Sluyter R, Shemon AN, Li C, et al. A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet (2002) 359:1114–9.10.1016/S0140-6736(02)08156-4 PubMed DOI
Thunberg U, Tobin G, Johnson A, Soderberg O, Padyukov L, Hultdin M, et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet (2002) 360:1935–9.10.1016/S0140-6736(02)11917-9 PubMed DOI
Zhang LY, Ibbotson RE, Orchard JA, Gardiner AC, Seear RV, Chase AJ, et al. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia (2003) 17:2097–100.10.1038/sj.leu.2403125 PubMed DOI
Starczynski J, Pepper C, Pratt G, Hooper L, Thomas A, Hoy T, et al. The P2X7 receptor gene polymorphism 1513 A – >C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. Br J Haematol (2003) 123:66–71.10.1046/j.1365-2141.2003.04563.x PubMed DOI
Nuckel H, Frey UH, Durig J, Duhrsen U, Siffert W. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome. Eur J Haematol (2004) 72:259–63.10.1111/j.0902-4441.2003.00210.x PubMed DOI
Paneesha S, Starczynski J, Pepper C, Delgado J, Hooper L, Fegan C, et al. The P2X7 receptor gene polymorphism 1513 A – >C has no effect on clinical prognostic markers and survival in multiple myeloma. Leuk Lymphoma (2006) 47:281–4.10.1080/10428190500305901 PubMed DOI
Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ (2015) 22:58–73.10.1038/cdd.2014.137 PubMed DOI PMC
Aquea G, Bresky G, Lancellotti D, Madariaga JA, Zaffiri V, Urzua U, et al. Increased expression of P2RY2, CD248 and EphB1 in gastric cancers from Chilean patients. Asian Pac J Cancer Prev (2014) 15:1931–6.10.7314/APJCP.2014.15.5.1931 PubMed DOI
Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, et al. Decreased mRNA expression in human breast cancer is associated with estrogen receptor-negative subtypes and poor prognosis. EBioMedicine (2015) 2:255–63.10.1016/j.ebiom.2015.01.008 PubMed DOI PMC
Lee YJ, Hah YJ, Kang YN, Kang KJ, Hwang JS, Chung WJ, et al. The autophagy-related marker LC3 can predict prognosis in human hepatocellular carcinoma. PLoS One (2013) 8:e81540.10.1371/journal.pone.0081540 PubMed DOI PMC
Ko YH, Cho YS, Won HS, Jeon EK, An HJ, Hong SU, et al. Prognostic significance of autophagy-related protein expression in resected pancreatic ductal adenocarcinoma. Pancreas (2013) 42:829–35.10.1097/MPA.0b013e318279d0dc PubMed DOI
Pulte D, Furman RR, Broekman MJ, Drosopoulos JH, Ballard HS, Olson KE, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk (2011) 11:367–72.10.1016/j.clml.2011.06.005 PubMed DOI PMC
Perry C, Hazan-Halevy I, Kay S, Cipok M, Grisaru D, Deutsch V, et al. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia. Ann Hematol (2012) 91:1271–9.10.1007/s00277-012-1425-2 PubMed DOI
Aliagas E, Vidal A, Texido L, Ponce J, Condom E, Martin-Satue M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediators Inflamm (2014) 2014:509027.10.1155/2014/509027 PubMed DOI PMC
Kunzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol (2007) 292:G223–30.10.1152/ajpgi.00259.2006 PubMed DOI
Xu S, Shao QQ, Sun JT, Yang N, Xie Q, Wang DH, et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol (2013) 15:1160–72.10.1093/neuonc/not067 PubMed DOI PMC
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 8:445–544.10.4161/auto.19496 PubMed DOI PMC
Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity (2013) 39:211–27.10.1016/j.immuni.2013.07.017 PubMed DOI
Ko A, Kanehisa A, Martins I, Senovilla L, Chargari C, Dugue D, et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ (2014) 21:92–9.10.1038/cdd.2013.124 PubMed DOI PMC
Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, et al. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy (2012) 8:1175–84.10.4161/auto.20353 PubMed DOI PMC
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418:191–5.10.1038/nature00858 PubMed DOI
Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, et al. Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol (2013) 1004:43–56.10.1007/978-1-62703-383-1_4 PubMed DOI
Liu A, Fang H, Dirsch O, Jin H, Dahmen U. Oxidation of HMGB1 causes attenuation of its pro-inflammatory activity and occurs during liver ischemia and reperfusion. PLoS One (2012) 7:e35379.10.1371/journal.pone.0035379 PubMed DOI PMC
Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med (2012) 209:1519–28.10.1084/jem.20120189 PubMed DOI PMC
Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. Front Physiol (2015) 6:93.10.3389/fphys.2015.00093 PubMed DOI PMC
Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol (2007) 81:84–91.10.1189/jlb.0306171 PubMed DOI
Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med (2012) 209:551–63.10.1084/jem.20111739 PubMed DOI PMC
Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 5:825–30.10.1038/sj.embor.7400205 PubMed DOI PMC
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 220:47–59.10.1111/j.1600-065X.2007.00573.x PubMed DOI
Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol (2010) 28:367–88.10.1146/annurev.immunol.021908.132603 PubMed DOI
Shiratsuchi A, Watanabe I, Takeuchi O, Akira S, Nakanishi Y. Inhibitory effect of toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol (2004) 172:2039–47.10.4049/jimmunol.172.4.2039 PubMed DOI
Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8:487–96.10.1038/ni1457 PubMed DOI
Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 13:832–42.10.1038/ni.2376 PubMed DOI PMC
Bao G, Qiao Q, Zhao H, He X. Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol (2010) 8:52.10.1186/1477-7819-8-52 PubMed DOI PMC
Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2014) 21:69–78.10.1038/cdd.2013.72 PubMed DOI PMC
Peng RQ, Wu XJ, Ding Y, Li CY, Yu XJ, Zhang X, et al. Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer. BMC Cancer (2010) 10:496.10.1186/1471-2407-10-496 PubMed DOI PMC
Yang GL, Zhang LH, Bo JJ, Huo XJ, Chen HG, Cao M, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol (2012) 106:57–61.10.1002/jso.23040 PubMed DOI
Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol (2008) 216:167–75.10.1002/path.2391 PubMed DOI
Yao X, Zhao G, Yang H, Hong X, Bie L, Liu G. Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma. J Cancer Res Clin Oncol (2010) 136:677–84.10.1007/s00432-009-0706-1 PubMed DOI
Liu F, Zhang Y, Peng Z, Gao H, Xu L, Chen M. High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J Transl Med (2012) 10:135.10.1186/1479-5876-10-135 PubMed DOI PMC
Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, et al. The association of HMGB1 gene with the prognosis of HCC. PLoS One (2014) 9:e89097.10.1371/journal.pone.0089097 PubMed DOI PMC
Liu Y, Xie C, Zhang X, Huang D, Zhou X, Tan P, et al. Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance. Eur J Cancer (2010) 46:3007–15.10.1016/j.ejca.2010.07.016 PubMed DOI
Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH, Zheng DY, et al. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res (2014) 4:369–77. PubMed PMC
Xu HL, Xu WH, Cai Q, Feng M, Long J, Zheng W, et al. Polymorphisms and haplotypes in the caspase-3, caspase-7, and caspase-8 genes and risk for endometrial cancer: a population-based, case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev (2009) 18:2114–22.10.1158/1055-9965.EPI-09-0152 PubMed DOI PMC
Theodoropoulos GE, Gazouli M, Vaiopoulou A, Leandrou M, Nikouli S, Vassou E, et al. Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis. Int J Colorectal Dis (2011) 26:1113–8.10.1007/s00384-011-1217-5 PubMed DOI
Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, et al. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest (2013) 43:286–91.10.1111/eci.12043 PubMed DOI
Lee H, Song M, Shin N, Shin CH, Min BS, Kim HS, et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas. PLoS One (2012) 7:e34318.10.1371/journal.pone.0034318 PubMed DOI PMC
Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, et al. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 132:2349–58.10.1002/ijc.27894 PubMed DOI
Qiu G, Li Y, Liu Z, Wang M, Ge J, Bai X. Clinical value of serum HMGB1 in diagnosis and prognosis of laryngeal squamous cell carcinoma. Med Oncol (2014) 31:316.10.1007/s12032-014-0316-x PubMed DOI
Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, et al. Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer (2013) 13:205.10.1186/1471-2407-13-205 PubMed DOI PMC
Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, et al. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer (2013) 133:2619–30.10.1002/ijc.28294 PubMed DOI
Chung HW, Lim JB, Jang S, Lee KJ, Park KH, Song SY. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci (2012) 103:1714–21.10.1111/j.1349-7006.2012.02358.x PubMed DOI PMC
Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 21:1212–23.10.1038/mt.2013.51 PubMed DOI PMC
Liikanen I, Koski A, Merisalo-Soikkeli M, Hemminki O, Oksanen M, Kairemo K, et al. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology (2015) 4:e989771.10.4161/2162402X.2014.989771 PubMed DOI PMC
Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010) 102:908–15.10.1038/sj.bjc.6605558 PubMed DOI PMC
Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res (2012) 18:5203–11.10.1158/1078-0432.CCR-12-0845 PubMed DOI
Kim KH, Jo MS, Suh DS, Yoon MS, Shin DH, Lee JH, et al. Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers. World J Surg Oncol (2012) 10:193.10.1186/1477-7819-10-193 PubMed DOI PMC
Zhu Y, Huang JM, Zhang GN, Zha X, Deng BF. Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells. J Transl Med (2012) 10:77.10.1186/1479-5876-10-77 PubMed DOI PMC
Pan H, He L, Wang B, Niu W. The relationship between RAGE gene four common polymorphisms and breast cancer risk in northeastern Han Chinese. Sci Rep (2014) 4:4355.10.1038/srep04355 PubMed DOI PMC
Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T. Receptor for advanced glycation end products (RAGE) – soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest (2007) 25:720–5.10.1080/07357900701560521 PubMed DOI
Wang D, Li T, Ye G, Shen Z, Hu Y, Mou T, et al. Overexpression of the receptor for advanced glycation endproducts (RAGE) is associated with poor prognosis in gastric cancer. PLoS One (2015) 10:e0122697.10.1371/journal.pone.0122697 PubMed DOI PMC
Kohles N, Nagel D, Jungst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol (2012) 33:2401–9.10.1007/s13277-012-0504-2 PubMed DOI
Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, et al. RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS One (2012) 7:e43734.10.1371/journal.pone.0043734 PubMed DOI PMC
Zhang S, Hou X, Zi S, Wang Y, Chen L, Kong B. Polymorphisms of receptor for advanced glycation end products and risk of epithelial ovarian cancer in Chinese patients. Cell Physiol Biochem (2013) 31:525–31.10.1159/000350073 PubMed DOI
Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci (2007) 98:1790–4.10.1111/j.1349-7006.2007.00590.x PubMed DOI PMC
Junjie X, Songyao J, Minmin S, Yanyan S, Baiyong S, Xiaxing D, et al. The association between toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer (2012) 12:57.10.1186/1471-2407-12-57 PubMed DOI PMC
Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun (2006) 7:615–24.10.1038/sj.gene.6364337 PubMed DOI
Mandal RK, George GP, Mittal RD. Association of toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. Mol Biol Rep (2012) 39:7263–9.10.1007/s11033-012-1556-5 PubMed DOI
Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med (2011) 9:139.10.1186/1479-5876-9-139 PubMed DOI PMC
Tittarelli A, Gonzalez FE, Pereda C, Mora G, Munoz L, Saffie C, et al. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother (2012) 61:2067–77.10.1007/s00262-012-1268-7 PubMed DOI PMC
Gast A, Bermejo JL, Claus R, Brandt A, Weires M, Weber A, et al. Association of inherited variation in toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One (2011) 6:e24370.10.1371/journal.pone.0024370 PubMed DOI PMC
Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ. Sequence variants of toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 65:11771–8.10.1158/0008-5472.CAN-05-2078 PubMed DOI
Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate (2009) 69:874–85.10.1002/pros.20933 PubMed DOI PMC
Song J, Kim DY, Kim CS, Kim HJ, Lee DH, Lee HM, et al. The association between toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet (2009) 190:88–92.10.1016/j.cancergencyto.2008.12.011 PubMed DOI
Kang R, Zhang Q, Zeh HJ, III, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 19:4046–57.10.1158/1078-0432.CCR-13-0495 PubMed DOI PMC
Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. Nat Cell Biol (2014) 16:728–36.10.1038/ncb3005 PubMed DOI
Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature (2012) 485:251–5.10.1038/nature10992 PubMed DOI PMC
West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature (2015) 520:553–7.10.1038/nature14156 PubMed DOI PMC
Cao H, Ye H, Sun Z, Shen X, Song Z, Wu X, et al. Circulatory mitochondrial DNA is a pro-inflammatory agent in maintenance hemodialysis patients. PLoS One (2014) 9:e113179.10.1371/journal.pone.0113179 PubMed DOI PMC
Kung CT, Hsiao SY, Tsai TC, Su CM, Chang WN, Huang CR, et al. Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. J Transl Med (2012) 10:130.10.1186/1479-5876-10-130 PubMed DOI PMC
Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med (1982) 155:264–75.10.1084/jem.155.1.264 PubMed DOI PMC
Rabiet MJ, Huet E, Boulay F. Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol (2005) 35:2486–95.10.1002/eji.200526338 PubMed DOI
Crouser ED, Shao G, Julian MW, Macre JE, Shadel GS, Tridandapani S, et al. Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Crit Care Med (2009) 37:2000–9.10.1097/CCM.0b013e3181a001ae PubMed DOI PMC
McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (2010) 330:362–6.10.1126/science.1195491 PubMed DOI
Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent immune activators that activate human neutrophils via FPR-1. J Trauma (2010) 68:1328–32.10.1097/TA.0b013e3181dcd28d PubMed DOI
Dieude M, Striegl H, Tyznik AJ, Wang J, Behar SM, Piccirillo CA, et al. Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T cells in the normal murine repertoire. J Immunol (2011) 186:4771–81.10.4049/jimmunol.1000921 PubMed DOI PMC
Bezu L, Gomes-De-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 6:187.10.3389/fimmu.2015.00187 PubMed DOI PMC
Trial watch: chemotherapy-induced immunogenic cell death in oncology
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
Detection of immunogenic cell death and its relevance for cancer therapy
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Trial watch: Immune checkpoint blockers for cancer therapy
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
